A Cost-Effectiveness Clinical Decision Analysis Model for Treatment of Schizophrenia

Palmer, Cynthia S.; Brunner, Elizabeth; Ruiz-Flores, Luis Guillermo; Páez-Agraz, Francisco; Revicki, Dennis A.

doi:10.1016/s0188-4409(02)00409-5

Cited by 44 publications

(68 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent models tend to be based on observed data from systematic reviews, clinical trials or large observational databases. 32,33,[153][154][155][156][157][158][159][160] However, most of the studies have been limited in scale and methodology. Particular issues of concern are first, that with the exception of RCTs, 73,[143][144][145][146][147]149,151,152 most of the studies do not use clear and adequate methods to control bias.…”

Section: The Economics Of Schizophreniamentioning

confidence: 99%

“…Nearly all the evaluations found that the new atypical antipsychotics were costeffective. 32,117,[130][131][132][133]135,137,139,141,[146][147][148]150,[152][153][154][155][157][158][159][160] The majority of comparisons of new atypical antipsychotics and conventional drugs considered risperidone or olanzapine. The systematic review and model by Bagnall and colleagues 32 considered a number of other new drugs in addition to these.…”

Section: The Economics Of Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Lewis

Davies²,

Jones³

et al. 2006

Health Technol Assess

135

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: SW Lewis received support for travel to meetings and honoraria for consultancies from AstraZeneca, Lilly, BristolMyersSquibb, Pfizer, Janssen, Wyeth, Lundbeck, GlaxoSmithKline and Novartis. L Davies received funding for preparing papers and attendance at meetings from Janssen, Hoechst Marion Roussel, Pfizer, AstraZeneca and Lundbeck, and project funding from Novartis. PB Jones received travel support to academic meetings from companies manufacturing drugs used in this study, and unrestricted use of honoraria and consultancy fees for some work for academic use in his department and elsewhere. TRE Barnes received travel support to academic meetings and honoraria for consultancy from companies manufacturing drugs used in this study, plus the award of a grant from Sanofi-Synthelabo for an investigator-initiated study. RM Murray received honoraria and advisory fees from pharmaceutical companies (paid into departmental research funds). R Kerwin received honoraria and advisory fees from pharmaceutical companies and received research grants for non-clinical research from Novartis. D Taylor received honoraria for a lecture and consultancy from manufacturers of atypical antipsy...

show abstract

Section: The Economics Of Schizophreniamentioning

confidence: 99%

Section: The Economics Of Schizophreniamentioning

confidence: 99%

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Lewis

Davies²,

Jones³

et al. 2006

Health Technol Assess

135

View full text Add to dashboard Cite

show abstract

“…Di questi, quattro sono studi empirici [27][28][29][30] e quattro sono studi di simulazione [31][32][33][34].…”

Section: Risultatiunclassified

“…Il modello markoviano di Palmer et al (1998) [32] ha confrontato l'efficacia e i costi di tre antipsicotici, di cui due atipici (olanzapina e risperidone) e uno tipico (aloperidolo), nel trattamento della schizofrenia. Il modello è stato utilizzato per calcolare i rapporti di costo-efficacia dei tre trattamenti lungo un periodo di 5 anni.…”

Section: Studi DI Simulazioneunclassified

See 1 more Smart Citation

La valutazione economica del trattamento farmacologico con antipsicotici nella schizofrenia: una revisione sistematica della letteratura

Ravasio¹

2005

View full text Add to dashboard Cite

Farmeconomia e percorsi terapeutici 2005; 6 (1) © SEEd Tutti i diritti riservati R. Ravasio INTRODUZIONELa schizofrenia colpisce circa l'1% della popolazione generale, con un tasso di prevalenza dello 0,5-1% e con un'incidenza annua dello 0,1 0 / 00 [1]. Il tasso di mortalità ad essa associato risulta essere doppio rispetto a quello della popolazione generale [2]. I pazienti schizofrenici sono caratterizzati inoltre da maggiori rischi di comorbilità [3], di esclusione sociale [4] e da un alto rischio di suicidio (10-25%) [5]. Questo spiega come, a prescindere dallo stato di salute direttamente correlato alla patologia, le condizioni generali di salute di un paziente schizofrenico siano caratterizzate da una aspettativa di vita mediamente inferiore del 20% rispetto a quella della popolazione generale [6].Diversamente da altre malattie che possono essere trattate e guarite, questa è una malattia cronica che accompagna il paziente per tutta la vita. Di solito la schizofrenia vieLa valutazione economica del trattamento farmacologico con antipsicotici nella schizofrenia: una revisione sistematica della letteratura R. Ravasio* ABSTRACT Schizophrenia is a chronic, severe, and disabling brain disease. Approximately 1 percent of the population develops schizophrenia during their lifetime. Available treatments can relieve many symptoms, but most people with schizophrenia continue to suffer some symptoms throughout their lives; it has been estimated that no more than one in five individuals recovers completely. The introduction of second-generation antipsychotics, also defined as atypicals, has increased the therapeutic options available for individuals with schizophrenia. Potential benefits of these agents include a more favourable profile in terms of positive and negative symptoms, less adverse effects and better cognitive functioning than first-generation antipsychotics. It is uncertain whether atypical antipsychotic agents, as prescribed in ordinary practice, are a cost-effective alternative to conventional agents. This study examined the financial and clinical implications of using atypical antipsychotics in the treatment of schizophrenia, considering both related costs and consequences. To elaborate the paper, we reviewed 8 economical studies regarding the comparison between atypical and typical antipsychotics, published in the years 1998-2004. In 5 studies atypical antipsychotics were cost-saving compared to typical, in 2 studies they were cost-neutral and in one study they resulted cost-effective. Consequently typical antipsychotics were cost-saving just in one study.

show abstract

Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach

2006

View full text Add to dashboard Cite

We obtain the posterior predictive distribution of transition probabilities between symptom severity states over time for patients with schizophrenia by (i) employing a Bayesian meta-analysis of published clinical trials and observational studies to estimate the posterior distribution of parameters that guide changes in Positive and Negative Syndrome Scale (PANSS) scores over time and under the influence of various drugs and (ii) by propagating the variability from the posterior distributions of the parameters through a micro-simulation model that is formulated based on schizophrenia progression. Results show detailed differences among haloperidol, risperidone and olanzapine in controlling various levels of severities of positive, negative and joint symptoms over time. For example, risperidone seems best in controlling severe positive symptoms while olanzapine is the worst in that during the first quarter of drug treatment; however, olanzapine seems to be best in controlling severe negative symptoms across all four quarters of treatment while haloperidol is the worst in this regard. These details may further serve to better estimate quality of life of patients and aid in resource utilization decisions in treating schizophrenic patients. In addition, consistent estimation of uncertainty in the time-profile parameters also has important implications for the practice of cost-effectiveness analysis and for future resource allocation policies in schizophrenia treatment.

show abstract

A Cost-Effectiveness Clinical Decision Analysis Model for Treatment of Schizophrenia

Cited by 44 publications

References 18 publications

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

La valutazione economica del trattamento farmacologico con antipsicotici nella schizofrenia: una revisione sistematica della letteratura

Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach

Contact Info

Product

Resources

About